Guilford Gliadel to be priced at $6,000 to $8,000 per treatment, CEO tells analysts.
GUILFORD GLIADEL WILL COST $6,000 TO $8,000 PER TREATMENT, which consists of eight polymer wafers containing the chemotherapeutic agent carmustine, Guilford CEO Craig Smith, MD, told analysts at the Alex. Brown conference in Baltimore. A Treatment IND for Gliadel is approaching 75 patients enrolled, Smith said. The company filed an NDA for Gliadel for the treatment of malignant glioma as an adjunct to brain surgery in February, and the product will be reviewed by the FDA Oncologic Drugs Advisory Committee on June 14 ("The Pink Sheet" May 13, In Brief).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth